The Company’s Proposed Cannabidiol
Delivery System Utilizes its Proprietary Cannabidiol (“CBD”)
Infused Chewing Gum Platform
NEW YORK, NY -- August 31, 2021 -- InvestorsHub NewsWire --
Tauriga Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a New York based diversified Life
Sciences Company, has announced that it has initiated a clinical
trial to examine the effects of Cannabidiol (“CBD”) doses on
pregnant women with the diagnosis of: Hyperemesis Gravidarum
(“Morning Sickness”). More specifically, this clinical trial
has been planned as a prospective, double-blind, placebo-controlled
study, to examine the: Effects of Different Cannabidiol Doses on
Reducing the Frequency and Severity of Nausea in Otherwise Healthy
Pregnant Women with Excessive First Trimester Emesis and the
Diagnosis of Hyperemesis Gravidarum.
This planned Clinical Trial will launch the Company’s
pharmaceutical development initiative and will secure Tauriga
Sciences Inc. as the only Company evaluating Cannabidiol in this
specific patient population.
The Company’s proposed Cannabidiol delivery system, utilizes its
proprietary Cannabidiol infused chewing gum platform. This
focuses on Sublingual Delivery, which refers to the pharmacological
route of administration by which substances diffuse into the blood
through tissues under the tongue. The Company expects to
develop “mission critical” versions of its proprietary chewing gum,
incorporating varying concentrations of CBD (potentially combined
with other substances).
The Company is currently in the process of finalizing the study
protocol, to be submitted, reviewed, and approved by a central
Institutional Review Board (“IRB”). The Company’s efforts,
with respect to this corporative initiative, are being spearheaded
by its Chief Medical Officer – Dr. Keith Aqua.
Tauriga’s Chief Medical Officer, Dr. Keith Aqua, commented,
“Nausea and vomiting in early pregnancy are both significant
physical and psychological health risks. Pregnant women frequently
ingest multiple medications for which there is little data on the
effectiveness and safety for both themselves or their developing
fetuses. Roughly 5% of pregnant women consume some form of
cannabinoid, the two most common being CBD and THC. Unlike alcohol,
to date, no known syndrome or specific birth defect has been
identified to be caused by these products. Despite being considered
a vulnerable population, pregnant women have few clinical trials
presenting rigorous scientific data to understand how these
molecules interact with the mother and fetus. We intend to add to
the fund of knowledge regarding the effects of CBD on pregnant
women by performing this and other scientific clinical trials.”
This Corporate Initiative, is in addition to its ongoing
Pharmaceutical development efforts – Targeting: Patients Subjected
to Ongoing Chemotherapy Treatment. This relates to the
development of its previously disclosed, Cannabinoid based,
Pharmaceutical grade version of Tauri-Gum™ -- for nausea
regulation.
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and
initiatives. The company manufactures and distributes
several proprietary retail products and product lines, mainly
focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles
market segment. The main product line, branded as
Tauri-Gum™, consists of a proprietary supplement chewing gum that
is Kosher certified, Halal certified, and Vegan Formulated (CBD
Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG
Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (DELTA 8
THC Infused Tauri-Gum™ Flavor: Evergreen Mint), (Vitamin C + Zinc
Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused
Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused
Tauri-Gum™ Flavor: Golden Raspberry). The Company’s
commercialization strategy consists of a broad array of retail
customers, distributors, and a fast-growing E-Commerce business
segment (E-Commerce website: www.taurigum.com). Please visit
our corporate website, for additional information, as well as
inquiries, at http://www.tauriga.com
Complementary to the Company’s retail business, is its ongoing
Pharmaceutical Development initiative. This relates to the
development of a proposed Pharmaceutical grade version of
Tauri-Gum™, for nausea regulation (specifically designed for the
following indication: Patients Subjected to Ongoing Chemotherapy
Treatment). On March 22, 2021, the Company announced that it had
Converted its U.S. Provisional Patent Application (filed on March
17, 2020) into a U.S. Non-Provisional Patent
Application. The Patent, filed with the U.S.P.T.O. is
Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND
METHODS OF TREATMENT”. On December 18, 2020 the Company
disclosed that it had entered into a Master Services Agreement with
CSTI to lead the Company's clinical development efforts.
The Company is headquartered in Wappingers Falls, New
York. In addition, the Company operates two full time
E-Commerce fulfillment centers: one located in Montgomery, Texas
and the other in Brooklyn, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements”
as defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning
future events. These forward-looking statements are often indicated
by using words such as “may,” “will,” “expects,” “anticipates,”
believes, “hopes,” “believes,” or plans, and may include statements
regarding corporate objectives as well as the attainment of certain
corporate goals and milestones. Forward-looking statements are
based on present circumstances and on management’s present beliefs
with respect to events that have not occurred, that may not occur,
or that may occur with different consequences or timing than those
now assumed or anticipated. Actual results may differ materially
from those expressed in forward looking statements due to known and
unknown risks and uncertainties, such as are not guarantees of
general economic and business conditions, the ability to
successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other periodic filings made from time to time with the
Securities and Exchange Commission. Such forward-looking statements
are made only as of the date of this release, and Tauriga assumes
no obligation to update forward-looking statements to reflect
subsequent events or circumstances. You should not place undue
reliance on these forward-looking statements.
Contact:
Tauriga Sciences, Inc.
4 Nancy Court, Suite 4
Wappingers Falls, NY 12590
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Company Instagram: @taurigum
Personal Instagram: @sethsms47
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Oct 2023 to Nov 2023
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Nov 2022 to Nov 2023
